Prognostic value of interleukin 2 and interleukin 15 in peritumoral hepatic tissues for patients with hepatitis B-related hepatocellular carcinoma after curative resection

Gut

Volumn 59, Issue 12, 2010, Pages 1699-1708

  Zhou, Haijun ^a,b   Huang, Hua ^a,b   Shi, Jiong ^a,b   Zhao, Yue ^a,b   Dong, Qiongzhu ^a,b   Jia, Huliang ^a,b   Liu, Yinkun ^a,b   Ye, Qinghai ^a,b   Sun, Huichuan ^a,b   Zhu, Xiaodong ^a,b   Fu, Liyun ^a,b   Guo, Kun ^a,b   Gao, Dongmei ^a,b   Sun, Jian ^a,b   Yan, Zhaowei ^a,b   Ren, Ning ^a,b   Tang, Zhaoyou ^a,b   Qin, Lunxiu ^a,b  

^a FUDAN UNIVERSITY   (China)

^b BEIJING UNIVERSITY OF POSTS AND TELECOMMUNICATIONS   (China)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 15; INTERLEUKIN 2;

ARTICLE; CANCER RECURRENCE; COHORT ANALYSIS; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER; LIVER CELL CARCINOMA; LIVER RESECTION; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS;

CARCINOMA, HEPATOCELLULAR; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPIDEMIOLOGIC METHODS; FEMALE; HEPATECTOMY; HEPATITIS B; HUMANS; INTERLEUKIN-15; INTERLEUKIN-2; LIVER NEOPLASMS; MALE; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 78649820763     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gut.2010.218404     Document Type: Article

References (47)

1. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003;362:1907-17.
2. Jepsen P, Vilstrup H, Tarone RE, et al. Incidence rates of hepatocellular carcinoma in the U.S. and Denmark: recent trends. Int J Cancer 2007;121:1624-6. (Pubitemid 47328724)
3. El-Serag HB. Hepatocellular carcinoma: recent trends in the United States. Gastroenterology 2004;127(5 Suppl 1):S27-34.
4. Sherman M. Recurrence of hepatocellular carcinoma. N Engl J Med 2008;359:2045-7.
5. Wang JH, Changchien CS, Hu TH, et al. The efficacy of treatment schedules according to Barcelona Clinic Liver Cancer staging for hepatocellular carcinoma: survival analysis of 3,892 patients. Eur J Cancer 2008;44:1000-6.
6. Pons F, Varela M, Llovet JM. Staging systems in hepatocellular carcinoma. HPB (Oxford) 2005;7:35-41.
7. Bruix J, Llovet JM. Major achievements in hepatocellular carcinoma. Lancet 2009;373:614-16.
8. Llovet JM, Bruix J. Novel advancements in the management of hepatocellular carcinoma in 2008. J Hepatol 2008;48(Suppl 1):S20-37.
9. Mann CD, Neal CP, Garcea G, et al. Prognostic molecular markers in hepatocellular carcinoma: a systematic review. Eur J Cancer 2007;43:979-92.
10. Ye QH, Qin LX, Forgues M, et al. Predicting hepatitis B virus-positive metastatic hepatocellular carcinomas using gene expression profiling and supervised machine learning. Nat Med 2003;9:416-23.
11. Budhu A, Jia HL, Forgues M, et al. Identification of metastasis-related microRNAs in hepatocellular carcinoma. Hepatology 2008;47:897-907.
12. Lee JS, Chu IS, Heo J, et al. Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling. Hepatology 2004;40:667-76.
13. Iizuka N, Oka M, Yamada-Okabe H, et al. Oligonucleotide microarray for prediction of early intrahepatic recurrence of hepatocellular carcinoma after curative resection. Lancet 2003;361:923-9.
14. Hoshida Y, Villanueva A, Kobayashi M, et al. Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N Engl J Med 2008;359:1995-2004.
15. Budhu A, Forgues M, Ye QH, et al. Prediction of venous metastases, recurrence, and prognosis in hepatocellular carcinoma based on a unique immune response signature of the liver microenvironment. Cancer Cell 2006;10:99-111. (Pubitemid 44202603)
16. Hattori E, Okumoto K, Adachi T, et al. Possible contribution of circulating interleukin- 10 (IL-10) to anti-tumour immunity and prognosis in patients with unresectable hepatocellular carcinoma. Hepatol Res 2003;27:309-14.
17. Okumoto K, Hattori E, Tamura K, et al. Possible contribution of circulating transforming growth factor-beta1 to immunity and prognosis in unresectable hepatocellular carcinoma. Liver Int 2004;24:21-8.
18. Asakawa M, Kono H, Amemiya H, et al. Role of interleukin-18 and its receptor in hepatocellular carcinoma associated with hepatitis C virus infection. Int J Cancer 2006;118:564-70.
19. Ikeguchi M, Hirooka Y. Interleukin-2 gene expression is a new biological prognostic marker in hepatocellular carcinomas. Onkologie 2005;28:255-9.
20. Wulfkuhle JD, Liotta LA, Petricoin EF. Proteomic applications for the early detection of cancer. Nat Rev Cancer 2003;3:267-75.
21. Toyoda H, Kumada T, Kiriyama S, et al. Comparison of the usefulness of three staging systems for hepatocellular carcinoma (CLIP, BCLC, and JIS) in Japan. Am J Gastroenterol 2005;100:1764-71. (Pubitemid 41648432)
22. Sun HC, Zhang W, Qin LX, et al. Positive serum hepatitis B e antigen is associated with higher risk of early recurrence and poorer survival in patients after curative resection of hepatitis B-related hepatocellular carcinoma. J Hepatol 2007;47:684-90.
23. Sun HC, Zhuang PY, Qin LX, et al. Incidence and prognostic values of lymph node metastasis in operable hepatocellular carcinoma and evaluation of routine complete lymphadenectomy. J Surg Oncol 2007;96:37-45.
24. Karmiris K, Paintaud G, Noman M, et al. Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn's disease. Gastroenterology 2009;137:1628-40.
25. Zhu XD, Zhang JB, Zhuang PY, et al. High expression of macrophage colony-stimulating factor in peritumoral liver tissue is associated with poor survival after curative resection of hepatocellular carcinoma. J Clin Oncol 2008;26:2707-16.
26. Llovet JM, Di Bisceglie AM, Bruix J, et al. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 2008;100:698-711.
27. Forbes JF, Cuzick J, Buzdar A, et al. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol 2008;9:45-53.
28. Dowsett M, Cuzick J, Wale C, et al. Retrospective analysis of time to recurrence in the ATAC trial according to hormone receptor status: an hypothesis-generating study. J Clin Oncol 2005;23:7512-17.
29. Galon J, Costes A, Sanchez-Cabo F, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006;313:1960-4.
30. Altman DG, Lausen B, Sauerbrei W, et al. Dangers of using "optimal" cutpoints in the evaluation of prognostic factors. J Natl Cancer Inst 1994;86:829-35.
31. Poon RT. Differentiating early and late recurrences after resection of HCC in cirrhotic patients: implications on surveillance, prevention, and treatment strategies. Ann Surg Oncol 2009;16:792-4.
32. Smyth MJ, Cretney E, Kershaw MH, et al. Cytokines in cancer immunity and immunotherapy. Immunol Rev 2004;202:275-93.
33. Rosenberg SA. Progress in human tumour immunology and immunotherapy. Nature 2001;411:380-4.
34. Bodnár A, Nizsalóczki E, Mocsár G, et al. A biophysical approach to IL-2 and IL-15 receptor function: localization, conformation and interactions. Immunol Lett 2008;116:117-25.
35. Waldmann TA, Tagaya Y. The multifaceted regulation of interleukin-15 expression and the role of this cytokine in NK cell differentiation and host response to intracellular pathogens. Annu Rev Immunol 1999;17:19-49.
36. Budhu A, Wang XW. The role of cytokines in hepatocellular carcinoma. J Leukoc Biol 2006;80:1197-213.
37. Portolani N, Coniglio A, Ghidoni S, et al. Early and late recurrence after liver resection for hepatocellular carcinoma: prognostic and therapeutic implications. Ann Surg 2006;243:229-35.
38. Kurokawa Y, Matoba R, Takemasa I, et al. Molecular-based prediction of early recurrence in hepatocellular carcinoma. J Hepatol 2004;41:284-91.
39. Ikeda K, Arase Y, Saitoh S, et al. Interferon beta prevents recurrence of hepatocellular carcinoma after complete resection or ablation of the primary tumour: a prospective randomized study of hepatitis C virus-related liver cancer. Hepatology 2000;32:228-32.
40. Takayama T, Sekine T, Makuuchi M, et al. Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial. Lancet 2000;356:802-7.
41. Lefkowitch JH. Liver biopsy assessment in chronic hepatitis. Arch Med Res 2007;38:634-43.
42. Rockey DC, Caldwell SH, Goodman ZD, et al. Liver biopsy. American Association for the Study of Liver Diseases. Hepatology 2009;49:1017-44.
43. Wang Y, Kato N, Hoshida Y, et al. Interleukin-1b gene polymorphisms associated with hepatocellular carcinoma in hepatitis C virus infection. Hepatology 2003;37:65-71.
44. Migita K, Miyazoe S, Maeda Y, et al. Cytokine gene polymorphisms in Japanese patients with hepatitis B virus infection-association betweenTGF-β1 polymorphisms and hepatocellular carcinoma. J. Hepatol 2005;42:505-10.
45. Zou W. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer 2005;5:263-74.
46. Kasprzak A, Seidel J, Adamek A, et al. Interleukin-2 (IL-2) expression in livers of patients with chronic hepatitis C virus (HCV) infection. Folia Histochem Cytobiol 2006;44:103-10.
47. Bergqvist A, Rice CM. Transcriptional activation of the interleukin-2 promoter by hepatitis C virus core protein. J Virol 2001;75:772-81. (Pubitemid 32037280)